Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
By I. D. de Boer, Kamlesh Khunti, Tami Sadusky, K. Tuttle, J. Neumiller, Connie M. Rhee, Sylvia E. Rosas, P. Rossing, G. Bakris. Diabetes Care, 2022
852 citations recorded by the source corpus.
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent clinical trials support new approaches to treat diabetes and CKD. The 2022 American Diabetes Association (ADA) Standards of Medical Care in Diabetes and the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease each provide evidence-based recommendations for management. A joint group of ADA and KDIGO representatives reviewed and developed a series of consensus statements to guide clinical care from the ADA and KDIGO guidelines. The published guidelines are aligned in the areas of CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management. Recommendations include comprehensive care in which pharmacotherapy that is proven to improve kidney and cardiovascular outcomes is layered on a foundation of healthy lifestyle. Consensus statements provide specific guidance on use of renin-angiotensin system inhibitors, metformin, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist. These areas of consensus provide clear direction for implementation of care to improve clinical outcomes of people with diabetes and CKD.
Subfields: Endocrinology, Diabetes and Metabolism, Nephrology
View Paper: https://www.semanticscholar.org/paper/4305b9e5d619333fc34440b89a285ca76b72e11f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association (2023, background): “121,139 In patients with a propensity for hyper-kalemia, the addition of an oral antihyperkalemic agent such as patiromer acetate or sodium zirconium cyclosili-cate may allow maintenance of an RAAS inhibitor without the risk of hyperkalemia.”
- A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, background): “58,69,80 The Kidney Disease Improving Global Outcomes CKD staging system combines eGFR and albuminuria to provide a broad risk estimate for CKD progression, CVD events, and overall mortality.”